Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Mol Cancer Res. 2015 Jun 1;13(9):1316–1324. doi: 10.1158/1541-7786.MCR-15-0120

Figure 5.

Figure 5

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated groups are compared all in A, E2F4>0 (B), and E2F4<0 NMIBC samples (C). IVT: intravesical BCG immunotherapy.